Infinity pulls trigger on Takeda oncology candidate option

Infinity Pharmaceuticals ($INFI) exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.

Infinity originally paid $5 million last July to obtain the option for the oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma.

The candidate is in Phase III trials for relapsed or refractory chronic lymphocytic leukemia and previously treated follicular lymphoma.

It is also in a Phase II trial for refractory indolent non-Hodgkin lymphoma.

- here's the release